Tolerability and safety and health outcomes in relapsing multiple sclerosis (MS) patients

Title
Tolerability and safety and health outcomes in relapsing multiple sclerosis (MS) patients

Type of intervention
Drug

Form of MS
Relapsing-remitting

Brief summary
A 4-month, Open-label, Multi-center Study to Explore Tolerability and Safety and Health Outcomes of FTY720 (Fingolimod) in Patients With Relapsing Forms of Multiple Sclerosis

Inclusion criteria

• Ages Eligible for Study: 18 Years to 65 Years
• Genders Eligible for Study: Both
• Accepts Healthy Volunteers: No
• Form of MS must have relapsing-remitting

Exclusion Criteria

• Patients with a type of MS that is not relapsing
• Patients with history of chronic immune disease
• Patients with a history of certain cancers
• Diabetic patients with certain eye disorders
• Patients who are on certain immunosuppressive medications or heart medications
• Patients with certain heart conditions
• Patients with certain lung conditions

Other protocol-defined inclusion/exclusion criteria may apply.

Anticipated start date

Recruitment status
Closed

Recruitment contacts
See link below

Further details
http://clinicaltrials.gov/ct2/show/study/NCT01127750?term=multiple+sclerosis+australia&rank=10&show_locs=Y#locn

Region
NSW, SA

Trial results

Last updated: May 2011